Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8983813 | PMC |
| http://dx.doi.org/10.3389/fncel.2022.875602 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Our Emerging Investigator Series features exceptional work by early-career researchers working in the field of materials science.
View Article and Find Full Text PDFExtending from Adaptation to Resilience Pathways: Perspectives from the Conceptual Framework to Key Insights.
Environ Manage
January 2025
TECNALIA Research & Innovation, Basque Research and Technology Alliance (BRTA), Energy, climate, and urban transition, Parque Tecnológico de Bizkaia, Derio, Spain.
The extent and timescale of climate change impacts remain uncertain, including global temperature increase, sea level rise, and more frequent and intense extreme events. Uncertainties are compounded by cascading effects. Nevertheless, decision-makers must take action.
View Article and Find Full Text PDFTesting for myelin oligodendrocyte glycoprotein antibodies: Who, what, where, when, why, and how.
Mult Scler
January 2025
Department of Neurology, Mayo Clinic, Rochester, MN, USA.
Testing for myelin oligodendrocyte glycoprotein immunoglobulin G antibodies (MOG-IgG) is essential to the diagnosis of MOG antibody-associated disease (MOGAD). Due to its central role in the evaluation of suspected inflammatory demyelinating disease, the last 5 years has been marked by an abundance of research into MOG-IgG testing ranging from appropriate patient selection, to assay performance, to utility of serum titers as well as cerebrospinal fluid (CSF) testing. In this review, we synthesize current knowledge pertaining to the "who, what, where, when, why, and how" of MOG-IgG testing, with the aim of facilitating accurate MOGAD diagnosis in clinical practice.
View Article and Find Full Text PDFExpanding Horizons in Parkinson's Disease: Towards Integrated Care and Comprehensive Research.
J Clin Med
January 2025
Research Department, Consorci Sanitari de l'Alt-Penedès i Garraf, 08720 Barcelona, Spain.
Parkinson's disease (PD) is the second most common neurodegenerative disorder worldwide and the fastest-growing neurological condition in terms of prevalence, disability, and mortality [...
View Article and Find Full Text PDFHSF1 at the crossroads of chemoresistance: from current insights to future horizons in cell death mechanisms.
Front Cell Dev Biol
January 2025
Department of Cell and Cancer Biology, College of Medicine and Life Sciences, The University of Toledo, Toledo, OH, United States.
Heat Shock Factor 1 (HSF1) is a major transcriptional factor regulating the heat shock response and has become a potential target for overcoming cancer chemoresistance. This review comprehensively examines HSF1's role in chemoresistance and its potential as a therapeutic target in cancer. We explore the complex, intricate mechanism that regulates the activation of HSF1, HSF1's function in promoting resistance to chemotherapy, and the strategies used to manipulate HSF1 for therapeutic benefit.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!